Actively Recruiting
Application of Cardiophrenic Lymphadenectomy in Advanced Ovarian Cancer: A Single-Center Prospective Exploratory Study
Led by manxiaxia · Updated on 2026-05-07
52
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study is to investigate the efficacy and safety of enucleation of enlarged CPLNs in patients with advanced ovarian cancer.
CONDITIONS
Official Title
Application of Cardiophrenic Lymphadenectomy in Advanced Ovarian Cancer: A Single-Center Prospective Exploratory Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with stage III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with imaging showing enlarged cardiophrenic lymph nodes (short axis ≥ 5 mm and ≤ 1 cm)
- Residual intra-abdominal tumor measuring 1 cm or less after cytoreductive surgery
- Female patients aged 18 to 70 years who are not pregnant or breastfeeding
- ECOG performance status of 0 or 1
- Adequate organ function including white blood cell count ≥ 2.5×10⁹/L, neutrophil count ≥ 1.5×10⁹/L, hemoglobin ≥ 90 g/L, platelets ≥ 100×10⁹/L; bilirubin ≤ 1.5 times upper limit of normal; ALT and AST ≤ 2.5 times upper limit of normal
- Serum creatinine ≤ 1.5 times normal value and creatinine clearance ≥ 60 ml/min
- Expected survival of 6 months or more
- Patient fully understands the study, consents to CPLN resection, voluntarily participates, and has signed informed consent
You will not qualify if you...
- Stage I or II epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
- Residual intra-abdominal tumor larger than 1 cm after cytoreductive surgery
- Imaging showing cardiophrenic lymph nodes with short axis greater than 1 cm
- Imaging showing mediastinal lymph node metastasis outside the cardiophrenic lymph nodes
- Other active malignant tumors within the past 5 years, except locally cured tumors such as basal cell carcinoma, squamous cell carcinoma of the skin, superficial bladder cancer, or in situ breast cancer
- Severe uncontrolled medical conditions including atrial fibrillation, angina, heart failure with ejection fraction less than 50%, uncontrolled hypertension, renal insufficiency, or uncontrolled infections
- Any unstable condition that may affect patient safety or trial compliance
- Currently receiving other anticancer drug treatments
- Refusal to sign the informed consent form
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the first hospital of JILIN UNIVERSITY
Changchun, Jilin, China, 130000
Actively Recruiting
Research Team
L
Li XIAOSEN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here